Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Connective Tissue Disease Companies

Connective tissue diseases (CTDs) encompass a group of disorders that affect the connective tissues, including the skin, joints, blood vessels, and internal organs. These diseases can have autoimmune or inflammatory components. While there may not be companies exclusively focused on connective tissue diseases, pharmaceutical companies, biotechnology firms, and research institutions may be actively involved in developing treatments and therapies for various CTDs.

Connective Tissue Disease Key Companies

Latest Connective Tissue Disease Companies Update

November 2023: Immunic Therapeutics Inc. acquired Celgene Corporation's late-stage development pipeline for Sjogren's syndrome, strengthening their focus on rare autoimmune diseases.July 2023: AbbVie entered into a collaboration with the Lupus Foundation of America to advance research and development efforts for Lupus.December 2023: Viela Bio Inc. secured $150 million in Series C funding to advance its pipeline of therapies for autoimmune and inflammatory diseases, including Scleroderma.September 2023: Biogen Inc. received $75 million in funding from the National Institutes of Health to develop a novel gene therapy for Myositis.January 2024: AstraZeneca received FDA approval for Uplizumab (Enbryta) for the treatment of moderate-to-severe Giant Cell Arteritis.October 2023: Roche launched Enspryng (satralizumab) in Europe for the treatment of neuromyelitis optica spectrum disorder.November 2023: The European League Against Rheumatism launched a new initiative to improve access to early diagnosis and treatment for patients with connective tissue diseases in low- and middle-income countries.

List of Connective Tissue Disease Key Companies in the Market

Abbott Laboratories

Bayer AG

Hoffmann-La Roche Ltd

Pfizer

AutoImmune Inc.

Johnson & Johnson

Amgen Inc.

AstraZeneca

Eli Lilly and Company

Biogen

LUPIN

Connective Tissue Disease Market Highlights:

Connective Tissue Disease Market Size

Connective Tissue Disease Market Trends

Connective Tissue Disease Market Analysis

Connective Tissue Disease Market Share

Connective Tissue Disease Market Highlights:

Connective Tissue Disease Market Trends

Connective Tissue Disease Market Analysis

Connective Tissue Disease Market Share

Connective Tissue Disease Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.